Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06408168 | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone… | Phase 2 | terminated | May 10, 2024 | M.D. Anderson Cancer Center | \<75% Participation | Other (stated, no rule matched) |
| NCT06536556 | Effects of a Single Chemotherapy Administration on Skeletal Muscle of Breast Cancer…(PROTECT-06-bis) | — | terminated | Aug 5, 2024 | Institut de cancérologie Strasbourg Europe | Recruitment sufficiant in term of statistical power | Enrollment / accrual |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2… | Phase 1 | terminated | Sep 23, 2022 | Baptist Health South Florida | Slow enrollment | Enrollment / accrual |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | Phase 2 | terminated | Aug 3, 2021 | PharmAbcine | Subject recruitment issues and follow-up study plans | Enrollment / accrual |
| NCT06613516 | Effect of Capivasertib on ctDNA in ER Positive Breast Cancer(CaptAin) | Phase 2 | withdrawn | Sep 26, 2024 | Imperial College London | Study was stopped because funder pulled funding for the study. 2 patients were screened however… | Enrollment / accrual |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast… | Phase 2 | terminated | Jul 21, 2017 | University of Chicago | side effects (rash) | Other (stated, no rule matched) |
| NCT03955640 | Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences | Phase 1 | terminated | May 20, 2019 | Thomas Jefferson University | PI decided not to move forward because of low accrual | Enrollment / accrual |
| NCT04534010 | Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts | N/A | terminated | Sep 1, 2020 | Stanford University | Sponsor decision due to low accrual | Enrollment / accrual |
| NCT06851442 | Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616… | Phase 1 / Phase 2 | terminated | Feb 28, 2025 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in…(TrasTUCAN) | Phase 2 | terminated | Oct 17, 2022 | Spanish Breast Cancer Research Group | The study was closed early due to safety concerns and an unfavorable benefit-risk balance.… | Safety / toxicity |
| NCT05957042 | Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment… | Early Phase 1 | withdrawn | Jul 24, 2023 | Milton S. Hershey Medical Center | Responsible Party left the institution and the study will not be started by other investigator | Investigator |
| NCT04188119 | A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in…(IMpALA) | Phase 2 | withdrawn | Dec 5, 2019 | The Christie NHS Foundation Trust | Unable to open | Other (stated, no rule matched) |
| NCT02688803 | Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to…(OTT15-04) | Phase 4 | terminated | Feb 23, 2016 | Ottawa Hospital Research Institute | The study did not meet the pilot feasibility endpoints and was formally closed to accrual… | Enrollment / accrual |
| NCT07150767 | A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human… | Phase 1 | withdrawn | Sep 2, 2025 | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | The applicant voluntarily withdrew the case | Other (stated, no rule matched) |
| NCT05180006 | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy(BIS-Program) | Phase 2 | terminated | Jan 6, 2022 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, ROCHE | Other (stated, no rule matched) |
| NCT07092475 | The Impact of Intraoperative Methadone on Postoperative Opioid Use | Phase 3 | withdrawn | Jul 30, 2025 | University of Utah | The study team will no longer be enrolling patients for this research. | Enrollment / accrual |
| NCT03284957 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other…(AMEERA-1) | Phase 1 / Phase 2 | terminated | Sep 15, 2017 | Sanofi | Sponsor decision to prematurely stop the study, not linked to any safety concern. | Safety / toxicity |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT05954143 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Phase 2 | terminated | Jul 20, 2023 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced… | Phase 1 | terminated | Oct 18, 2016 | Novartis Pharmaceuticals | The early termination was based on a business decision that FAZ053 would no longer be formulated… | Safety / toxicity |
| NCT07178665 | Pilot Trial of Preop Partial Radiation in Breast Cancer Patients | Phase 1 | suspended | Sep 17, 2025 | Rutgers, The State University of New Jersey | 10th patient enrolled; interim analysis to be completed by HROC after 3-month follow-up completed… | Efficacy / futility |
| NCT04024436 | A Study of TAS-120 in Patients With Metastatic Breast Cancer | Phase 2 | terminated | Jul 18, 2019 | Taiho Oncology, Inc. | The Sponsor decided to discontinue the study due to strategic considerations and not due to any… | Safety / toxicity |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant,… | Phase 2 | terminated | Jun 7, 2019 | Mayo Clinic | The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in… | Other (stated, no rule matched) |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT00556907 | Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of… | N/A | terminated | Nov 12, 2007 | University of Southern California | Lack of Funding | Funding |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally…(ELEVATE TNBC) | Phase 2 | terminated | Jul 12, 2021 | Gilead Sciences | Sponsor decision to terminate study. | Sponsor / business decision |
| NCT05634954 | Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally… | Phase 1 | withdrawn | Dec 2, 2022 | GE Healthcare | Business Decision | Sponsor / business decision |
| NCT00210236 | Surgical Breast Resection With or Without Axillary Lymph Node Excision in Treating Women…(AXIL95) | Phase 3 | terminated | Sep 21, 2005 | Institut Bergonié | not stated | Not stated |
| NCT04419181 | Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | Phase 2 | withdrawn | Jun 5, 2020 | University of Rochester | Change in the landscape of current treatment of early stage breast cancer. Larger clinical trials… | Other (stated, no rule matched) |
| NCT04794816 | What Women Want: Real Time Results During Screening Mammography in the Era of… | — | withdrawn | Mar 12, 2021 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Phase 1 | terminated | Jul 29, 2021 | Taiho Oncology, Inc. | After careful review of Taiho's ongoing portfolio and data obtained so far in the context of… | Safety / toxicity |
| NCT06275854 | YASU Research Registry: For Young Adults With Cancer | — | terminated | Feb 23, 2024 | Young Adult Survivors United | Sponsoring organization no longer desired to recruit/maintain registry | Enrollment / accrual |
| NCT03901469 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer(TNBC) | Phase 2 | terminated | Apr 3, 2019 | Zenith Epigenetics | Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued… | Safety / toxicity |
| NCT03598712 | Local Compression Seroma DIminution Objective (CLODIS)(CLODIS) | Phase 3 | terminated | Jul 26, 2018 | Centre Francois Baclesse | Surgical practices have evolved as surgeons practice immediate reconstructive surgery. We have not… | Enrollment / accrual |
| NCT04136912 | 3-D Super Resolution Ultrasound Microvascular Imaging | Phase 2 | terminated | Oct 23, 2019 | UNC Lineberger Comprehensive Cancer Center | Grant ended | Other (stated, no rule matched) |
| NCT04108858 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance… | Phase 1 / Phase 2 | terminated | Sep 30, 2019 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03284346 | Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer… | N/A | terminated | Sep 15, 2017 | University of Southern California | PI left | Investigator |
| NCT05807074 | Impact of Topical Tranexamic Acid in Breast Reconstruction | Phase 4 | terminated | Apr 10, 2023 | University of California, San Francisco | Slow Accrual | Enrollment / accrual |
| NCT03535506 | Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for…(WI223281) | Phase 2 | terminated | May 24, 2018 | Georgetown University | lack of accrual | Enrollment / accrual |
| NCT03974204 | Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion… | N/A | withdrawn | Jun 4, 2019 | Centre Oscar Lambret | Modification of the care habits. We believe today that we are no longer able to carry out this… | Other (stated, no rule matched) |
| NCT06597773 | Online Patient Navigation Program for Patients With Breast Cancer | N/A | withdrawn | Sep 19, 2024 | Medicos e Investigadores en la Lucha contra el Cancer de Mama | It was not possible to develop and implement the intervention due to lack of funding. | Funding |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT05425550 | Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive…(PRO2) | N/A | terminated | Jun 21, 2022 | Palleos Healthcare GmbH | The study was discontinued due to low recruitment rates. Despite various measures, such as training… | Enrollment / accrual |
| NCT04191382 | Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal…(AMEERA-4) | Phase 2 | terminated | Dec 9, 2019 | Sanofi | early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT06672224 | Indocyanine Green Fluoroscopy and SPY Angiography for the Assessment of Lymphatic… | N/A | withdrawn | Nov 4, 2024 | City of Hope Medical Center | low accrual | Enrollment / accrual |
| NCT04249622 | Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based… | Phase 2 | terminated | Jan 31, 2020 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05128773 | Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone…(AMEERA-6) | Phase 3 | terminated | Nov 22, 2021 | Sanofi | Sponsor decision to prematurely stop the study, not linked to any safety concern | Safety / toxicity |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab… | Phase 1 / Phase 2 | terminated | Feb 20, 2020 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 5, 2026source: clinicaltrials